Lyell Immunopharma (LYEL) Stock: Buy, Sell, or Hold?
LYEL - Lyell Immunopharma, Inc. Common Stock
$11.04
-0.27 (-2.34%)
▼
5d:
+17.57%
30d:
+17.32%
90d:
-14.22%
WAIT
LOW Confidence
Analysis Updated: Oct 30, 2026 12:00 AM ET
Earnings: Nov 11, 2026
9d
Get Alerted When LYEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: LYEL shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: LYEL shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: LYEL is currently trading at $11.04, which is considered extended relative to its 30-day fair value range of $8.41 to $10.27.
Technical Outlook: Technically, LYEL is in a strong downtrend. Immediate support is located at $7.92, while resistance sits at $11.62.
Market Sentiment: LYEL scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $37.88 (+243.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LYEL is in a strong downtrend. Immediate support is located at $7.92, while resistance sits at $11.62.
Market Sentiment: LYEL scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $37.88 (+243.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.41 -
$10.27
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
37.5%
All Signals
- BEARISH: Price extended above range (+7.5% above its trading range)
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 243.1% below Wall St target ($37.88)
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.41 -
$10.27
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.29
(11.7%)
Support & Resistance Levels
Support Level
$7.92
Resistance Level
$11.62
Current Trend
Strong Downtrend
Technical data as of
Oct 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.75
Wall Street Target
$37.88
(+243.1%)
Revenue Growth (YoY)
-50.0%
Share & Embed Analysis
Last updated: November 01, 2026 1:11 AM ET
Data refreshes hourly during market hours. Next update: 1:11 AM
Data refreshes hourly during market hours. Next update: 1:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LYEL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1144 | 51 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 65 BUY |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 41 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 54 HOLD |
|
BNTX
BioNTech SE |
BUY
21 analysts |
$117 | 66 BUY |
